{"id":"conventional-dapt","safety":{"commonSideEffects":[{"rate":"2-5","effect":"Bleeding (major and minor)"},{"rate":"1-3","effect":"Gastrointestinal bleeding"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":null,"effect":"Bruising"},{"rate":"<0.1","effect":"Thrombotic thrombocytopenic purpura (TTP)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DAPT typically combines aspirin (which inhibits cyclooxygenase and thromboxane A2 production) with a P2Y12 receptor antagonist (such as clopidogrel, prasugrel, or ticagrelor) to provide complementary antiplatelet effects. This dual mechanism prevents platelet activation and aggregation more effectively than monotherapy, reducing the risk of stent thrombosis and recurrent ischemic events in cardiovascular patients.","oneSentence":"Conventional DAPT (Dual Antiplatelet Therapy) combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:15.630Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)"},{"name":"Secondary prevention of stent thrombosis post-PCI"},{"name":"Stable coronary artery disease with stent placement"}]},"trialDetails":[{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT07374718","phase":"NA","title":"Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2026-03-01","conditions":"Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR), Coronary Artery Disease (CAD)","enrollment":468},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT04755387","phase":"PHASE4","title":"Ticagrelor De-escalation Strategy in AMI Patients","status":"RECRUITING","sponsor":"Dong-A University","startDate":"2023-03-27","conditions":"Acute Myocardial Infarction","enrollment":2312},{"nctId":"NCT06665919","phase":"NA","title":"The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models","status":"COMPLETED","sponsor":"Vistamedi Ltd.","startDate":"2023-06-15","conditions":"Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis","enrollment":283},{"nctId":"NCT05066789","phase":"PHASE4","title":"CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2022-01-17","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT06718179","phase":"PHASE4","title":"Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-11-16","conditions":"Acute Coronary Syndrome","enrollment":3150},{"nctId":"NCT05418556","phase":"PHASE4","title":"Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-10-21","conditions":"Coronary Artery Disease","enrollment":3944},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT06339021","phase":"EARLY_PHASE1","title":"OCT or Angiography Guided De-escalation of DAPT","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2024-04-01","conditions":"Optical Coherence Tomography, Dual Antiplatelet Therapy, Antiplatelet De-escalation","enrollment":80},{"nctId":"NCT06283888","phase":"PHASE4","title":"CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"Zunyi Medical College","startDate":"2024-04-01","conditions":"ACS - Acute Coronary Syndrome, CYP2C19 Polymorphism","enrollment":1200},{"nctId":"NCT06013020","phase":"PHASE4","title":"Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus","status":"RECRUITING","sponsor":"Zunyi Medical College","startDate":"2024-04-01","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":374},{"nctId":"NCT05223335","phase":"PHASE4","title":"Clopidogrel Monotherapy in Patients With High Bleeding Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-03-29","conditions":"Bleeding Complications","enrollment":98},{"nctId":"NCT06084000","phase":"NA","title":"STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-10-15","conditions":"Drug-coated Balloon, Drug-eluting Stent, De Novo Stenosis","enrollment":2700},{"nctId":"NCT02601157","phase":"PHASE4","title":"Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-01-18","conditions":"Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction","enrollment":2173},{"nctId":"NCT05045274","phase":"NA","title":"The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-12","conditions":"STEMI - ST Elevation Myocardial Infarction, Left Ventricular Systolic Dysfunction","enrollment":300},{"nctId":"NCT04538924","phase":"NA","title":"Etiologic Mechanisms, Myocardial Changes and Prognosis of Patients With MINOCA","status":"UNKNOWN","sponsor":"Vilnius University Hospital Santaros Klinikos","startDate":"2019-01-01","conditions":"Myocardial Infarction With Nonobstructive Coronary Arteries","enrollment":150},{"nctId":"NCT01955200","phase":"PHASE4","title":"OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2013-10-05","conditions":"Coronary Artery Disease","enrollment":1724},{"nctId":"NCT03786757","phase":"PHASE3","title":"Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2019-04-01","conditions":"ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus","enrollment":200},{"nctId":"NCT03310801","phase":"","title":"LAAO With DAPT Versus Antithrombotic Therapy","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2016-08-01","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Unguided DAPT"],"phase":"marketed","status":"active","brandName":"Conventional DAPT","genericName":"Conventional DAPT","companyName":"Zunyi Medical College","companyId":"zunyi-medical-college","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Conventional DAPT (Dual Antiplatelet Therapy) combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Secondary prevention of stent thrombosis post-PCI, Stable coronary artery disease with stent placement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}